AKBA — Akebia Therapeutics, Inc.
$0.5669+0.84%
Last close: · regular session
After-hours $0.5600 -1.22% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for AKBA in the TickerWise workspace.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 181
- Website: https://www.akebia.com
Latest SEC filings for AKBA
Latest AKBA news
- Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 Read article
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.